Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study

Conclusions
In children aged 6–11 years with moderate-to-severe type 2 asthma, dupilumab treatment was associated with rapid, sustained improvements in asthma control. HRQoL was significantly improved for children and their caregivers.

Source: European Respiratory Journal - November 2, 2023 Category: Respiratory Medicine Authors: Fiocchi, A. G., Phipatanakul, W., Zeiger, R. S., Durrani, S. R., Cole, J., Msihid, J., Gall, R., Jacob-Nara, J. A., Deniz, Y., Rowe, P. J., Lederer, D. J., Hardin, M., Zhang, Y., Khan, A. H. Tags: Asthma and allergy Original Articles: Asthma in children Source Type: research